x
[contact-form-7 404 "Not Found"]

Oct2024

CorpusAnalytiX and Ariana Pharma Announce Collaborative Alliance to Accelerate AI-Driven Drug Development

Collaboration connects CorpusAnalytiX’s diverse healthcare data marketplace with Ariana Pharma’s Knowledge Extraction and Management eXplainable AI platform to fuel advanced pharmaceutical research.
October 15, 2024 – LONDON and PARIS: CorpusAnalytiX, a transformative healthcare data brokerage platform, and Ariana Pharma, a leading AI drug development company, today announced a strategic partnership to accelerate drug development and provide researchers access to previously siloed datasets critical for advancing innovation in pathology, oncology, genomics, and more, fueling deep scientific knowledge extraction using eXplainable AI. This collaboration will leverage CorpusAnalytiX’s extensive network of biomedical dataset suppliers and Ariana Pharma’s KEM® eXplainable AI platform to enable faster, more targeted R&D.
  • Key Highlights of the Partnership:
  • ● CorpusAnalytiX will provide Ariana Pharma with streamlined access to unique
    datasets from biotech SMEs, laboratories, and concierge clinics, strengthening
    Ariana Pharma’s impact in clinical development.
  • ● Ariana Pharma will utilize these datasets to provide access to innovative
    biomarker hypotheses through its KEM® xAI platform for improved patient
    selection, biomarker identification, and design of innovative clinical trial studies.
  • ● As part of the collaboration, Ariana Pharma will contribute to CorpusAnalytiX’s
    marketplace through xAI-derived insights and also expand the platform’s data
    offering.
  • ● The partnership aims to reduce drug development timelines and costs while
    increasing the success rates of clinical trials across multiple therapeutic areas
    with a strong focus on complex indications, rare diseases, and heterogeneous
    datasets.
“This collaboration represents a significant milestone in our mission to democratize access to healthcare datasets,” said Ansh Tandon, Founder and CEO of CorpusAnalytiX. “By integrating Ariana’s advanced AI capabilities with our growing network of data suppliers, we’re establishing a powerful ecosystem that can push forward innovation in drug development and precision medicine.”
    • Driving New Revenue Streams for Data Generators
One unique aspect of CorpusAnalytiX is its supplier-centric model, which empowers data generators—such as biotech startups and research labs—to maintain control over their datasets while monetizing them effectively. Unlike other platforms that aggregate and sell datasets directly, CorpusAnalytiX operates on a model that allows suppliers to set their own prices, ensuring equitable compensation and enabling suppliers to leverage their previously underutilized datasets.
Dr. Frédéric Parmentier, VP of Data Science at Ariana Pharma, added, “CorpusAnalytiX’s unique approach to connecting us with diverse, high-quality healthcare datasets aligns perfectly with our precision medicine platform, improving its fit to de-risk clinical development. This collaboration will enable us to design more effective drug trials, potentially leading to faster regulatory approvals and, ultimately, better patient outcomes.”
    • Streamlining Data Access for AI-Driven Drug Development
CorpusAnalytiX’s B2B marketplace simplifies the healthcare data acquisition process by linking biotech SMEs, university labs, and pharmaceutical companies with a network of US and EU data suppliers. The platform’s practical e-commerce interface allows prospective buyers to specify metadata and annotation requirements through custom queries, ensuring precise matching of research needs with available data. Buyers benefit from faster access to various datasets while suppliers manage their assets, choosing flexible licensing options and empowering them to become contract research organizations.
Through this partnership, Ariana Pharma will be able to tap into CorpusAnalytiX’s expanding repository, including:
  • ● Whole-exome sequencing data from over 20,000 genes
  • ● More than 10 million pathology whole slide images
  • ● 2 million+ HIPAA-compliant, de-identified electronic health records
  • ● Care pathways, simulations, multi-omics data, failed clinical trial information, and other niche datasets
    • Enhancing AI-Powered Precision Medicine
Ariana Pharma’s KEM® eXplainable AI platform integrates extensive pre-clinical, clinical, and real-world evidence data to de-risk clinical development by improving clinical trial design and execution. By incorporating CorpusAnalytiX’s vast ecosystem, Ariana Pharma aims to:
  • ● Refine patient stratification and biomarker identification
  • ● Propose innovative, precision medicine biomarker-based clinical study designs
  • ● Fast-track drug repurposing and indication expansion efforts
  • ● Bolster real-world evidence generation to support regulatory submissions
The collaboration will initially focus on oncology and rare diseases but will expand into other therapeutic areas as the partnership progresses. “By facilitating access to previously siloed datasets, we’re working to provide Ariana Pharma with a more varied pool of information” explained Tandon. “We believe this collaboration has the potential to contribute to reducing the time and cost associated with bringing new therapies to market.” Parmentier added, “The breadth and depth of data available through the CorpusAnalytiX platform could allow us to develop more robust xAI algorithms, potentially leading to more accurate predictions and better-designed clinical trials.”
    • About CorpusAnalytiX
CorpusAnalytiX is a B2B healthcare data brokerage that connects biotech SMEs, laboratories, researchers, and pharmaceutical companies with novel datasets from diverse sources such as pathology firms, D2C genetic testing startups, and concierge clinics. By streamlining data acquisition and unlocking access to unique datasets, CorpusAnalytiX’s one-stop-shop platform accelerates healthcare innovation. Unlock groundbreaking biomedical insights at www.corpusanalytix.com.
    • About Ariana Pharma
Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

Ariana Pharmaceuticals, The AI DRUG Development Company

Menu

Ariana Pharma © 2024 All Rights Reserved